Scholte M, Grimm SE, Pauly B, Verbeeck F, Pasmooij AMG, Bouma B, Van Duijn-Wiersma J, Guney E, Kesselheim AS, Schmidt HHHW, Joore MA - Drug Discovery Today
- Commentary & Opinion
- Innovation Incentives and Competition
- Regulation and Clinical Evidence
Summary:
Drug repurposing provisions included in EU pharmaceutical legislation have the potential to improve access to affordable treatments, but additional regulatory support, fair data protection periods, and improved awareness strategies are needed tomake repurposed drugs more accessible, affordable, and sustainable.
VIEW SOURCE
Recent Work from PORTAL
How Congress Can Fix Expert Advisory Committees
Daval CJR, Kesselheim AS - STAT
- Commentary & Opinion
- Regulation and Clinical Evidence
International Regulatory Status and Reimbursement Recommendations of Haematological Malignancy Drugs Withdrawn from the FDA Accelerated Approval Pathway
Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy
- Research Publications
- Price, Value, and Access
- Regulation and Clinical Evidence
Politics and the Patient Encounter, in Dire Times
Avorn J - MedPage Today
- Commentary & Opinion
- Regulation and Clinical Evidence
Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115
©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.